Amy Folsom
Medical · Sikeston, MONPI 1053400457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 25.7% of the total.
Across 337 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$909
- Lilly USA, LLC$411
- Novo Nordisk$402
- Otsuka America Pharmaceutical, Inc.$245
- Pfizer$215
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,635100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $1,451 |
| Amgen | 46 | $909 |
| Lilly USA, LLC | 27 | $411 |
| Novo Nordisk | 28 | $402 |
| Otsuka America Pharmaceutical, Inc. | 14 | $245 |
| Pfizer | 14 | $215 |
| Mylan Specialty L.p. | 13 | $214 |
| Novartis | 12 | $201 |
| AstraZeneca | 9 | $164 |
| Boehringer Ingelheim | 9 | $130 |
| Merck | 8 | $129 |
| Sunovion Pharmaceuticals Inc. | 13 | $123 |
| Sumitomo Pharma America, Inc. | 7 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $110 |
| GSK | 6 | $99 |
| Eisai Inc. | 3 | $87 |
| Dexcom, Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Ironwood Pharmaceuticals, Inc | 4 | $58 |
| Bayer | 2 | $41 |
| Lundbeck LLC | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Virtus Pharmaceuticals LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Gilead | 1 | $18 |
| Ardelyx, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Sanofi | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,635 in reported general payments places this provider in the 85th percentile of 198 medical providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 23 | $110,173 |
| MounjaroTirzepatide | 56 | $70,856 |
| FarxigaDapagliflozin Propanediol | 92 | $67,341 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $51,311 |
| LinzessLinaclotide | 81 | $44,262 |
| EliquisApixaban | 64 | $43,015 |
| VraylarCariprazine Hcl | 25 | $40,669 |
| OzempicSemaglutide | 30 | $34,496 |
| TrulicityDulaglutide | 24 | $29,784 |
| RybelsusSemaglutide | 28 | $29,038 |
| JanuviaSitagliptin Phosphate | 49 | $28,561 |
| Repatha SureclickEvolocumab | 31 | $23,431 |
| JardianceEmpagliflozin | 29 | $23,023 |
| MyrbetriqMirabegron | 26 | $13,062 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $909 | $110,17323 claims |
| Lilly USA, LLCMounjaro, Trulicity | $411 | $100,64080 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $164 | $86,718138 claims |
| AbbVieLinzess, Vraylar | $1,451 | $84,930106 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $99 | $63,867105 claims |
| Novo NordiskOzempic, Rybelsus | $402 | $63,53558 claims |
| PfizerEliquis | $215 | $43,01564 claims |
| MerckJanuvia | $129 | $28,56149 claims |
| Boehringer IngelheimJardiance | $130 | $23,02329 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $13,06226 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $65 | $10,34413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 medical providers in Missouri.
Other medical in Sikeston
- Bruce BraswellSikeston$7K
- Melanie ChisamSpringfield$92K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
- Dustin BartlettSpringfield$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Corey WhitesidesColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.